AIM Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
26.0K
+18.2%
22.0K
+4.8%
21.0K
-19.2%
26.0K
+4.0%
25.0K
Cost of Revenue
5.0K
+25.0%
4.0K
-90.0%
40.0K
-41.2%
68.0K
+580.0%
10.0K
Gross Profit
21.0K
+16.7%
18.0K
+194.7%
-19000
+54.8%
-42000
-380.0%
15.0K
Operating Expenses
3.5M
+57.5%
2.2M
-23.5%
2.9M
+22.0%
2.4M
-9.6%
2.7M
R&D
589.0K
+22.2%
482.0K
-54.7%
1.1M
+75.1%
607.0K
-48.3%
1.2M
SG&A
2.9M
+67.1%
1.8M
-5.8%
1.9M
+4.0%
1.8M
+20.9%
1.5M
Operating Income
-3513000
-57.8%
-2226000
+24.6%
-2952000
-20.6%
-2447000
+7.5%
-2646000
EBITDA
-2985000
-36.7%
-2183000
+25.0%
-2909000
-21.6%
-2393000
-2.8%
-2327000
Net Income
-3788000
-25.3%
-3023000
+27.6%
-4175000
-27.1%
-3284000
-17.5%
-2794000
EPS (Basic)
$-0.43
+37.7%
$-0.69
$-1.57
+57.3%
$-3.68
EPS (Diluted)
$-0.43
+37.7%
$-0.69
$-1.57
+57.3%
$-3.68
Shares (Diluted)
17.1M
+293.4%
4.4M
2.1M
+176.0%
759.3K
AIM ImmunoTech (AIM) — Financials